Manufacturer of Controlled Substances; Notice of Application, 11032 [05-4290]

Download as PDF 11032 Federal Register / Vol. 70, No. 43 / Monday, March 7, 2005 / Notices automated collection techniques or other forms of information technology. The PRA also requires agencies to estimate the total annual reporting ‘‘non-hour cost’’ burden to respondents or recordkeepers resulting from the collection of information. We have not identified non-hour cost burdens for this information collection. If you have costs to generate, maintain, and disclose this information, you should comment and provide your total capital and startup cost components or annual operation, maintenance, and purchase of service components. You should describe the methods you use to estimate major cost factors, including system and technology acquisition, expected useful life of capital equipment, discount rate(s), and the period over which you incur costs. Capital and startup costs include, among other items, computers and software you purchase to prepare for collecting information; monitoring, sampling, and testing equipment; and record storage facilities. Generally, your estimates should not include equipment or services purchased: (i) Before October 1, 1995; (ii) to comply with requirements not associated with the information collection; (iii) for reasons other than to provide information or keep records for the Government; or (iv) as part of customary and usual business or private practices. We will summarize written responses to this notice and address them in our ICR submission for OMB approval, including appropriate adjustments to the estimated burden. We will provide a copy of the ICR to you without charge upon request. The ICR also will be posted on our Web site at https:// www.mrm.mms.gov/Laws_R_D/ FRNotices/FRInfColl.htm. Public Comment Policy: We will post all comments in response to this notice on our Web site at https:// www.mrm.mms.gov/Laws_R_D/ FRNotices/FRInfColl.htm. We also will make copies of the comments available for public review, including names and addresses of respondents, during regular business hours at our offices in Lakewood, Colorado. Upon request, we will withhold an individual respondent’s home address from the public record, as allowable by law. There also may be circumstances in which we would withhold from the rulemaking record a respondent’s identity, as allowable by law. If you request that we withhold your name and/or address, state your request prominently at the beginning of your comment. However, we will not consider anonymous comments. We will make all submissions from VerDate jul<14>2003 18:49 Mar 04, 2005 Jkt 205001 organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, available for public inspection in their entirety. MMS Information Collection Clearance Officer: Arlene Bajusz (202) 208–7744. Dated: February 23, 2005. Richard Adamski, Acting Associate Director for Minerals Revenue Management. [FR Doc. 05–4333 Filed 3–4–05; 8:45 am] BILLING CODE 4310–MR–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 2, 2004, Norac, Inc., 405 S. Motor Avenue, PO Box 577, Azusa, California 91702, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of THC Tetrahydrocannabinols (7370), a basic class of controlled substance listed in Schedule I. The company plans to manufacture the listed controlled substances in bulk for formulation into the pharmaceutical controlled substance marinol. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: Federal Register Representative, Liaison and Policy Section (ODL) or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 6, 2005. Dated: February 23, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–4290 Filed 3–4–05; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00098 Fmt 4703 Sfmt 4703 MEDICARE PAYMENT ADVISORY COMMISSION Commission Meeting Medicare Payment Advisory Commission. ACTION: Notice of meeting. AGENCY: SUMMARY: The Commission will hold its next public meeting on Thursday, March 10, 2005, and Friday, March 11, 2005, at the Ronald Reagan Building, International Trade Center, 1300 Pennsylvania Avenue, NW., Washington, DC. The meeting is tentatively scheduled to begin at 9:30 a.m. on March 10, and at 9 a.m. on March 11. Topics for discussion include findings on congressionally mandated studies on critical access hospitals and risk adjustment and other issues related to the adjusted average per capita cost (AAPCC). The Commission will also discuss Medicare Advantage plans, implementation issues with the new Medicare Part D benefit, outpatient pharmacy services in hospitals, and reform issues for various post-acute care settings. The Commission will also host a panel on the use of clinical- and costeffectiveness information by Medicare. Agendas will be e-mailed approximately one week prior to the meeting. The final agenda will be available on the Commission’s Web site (https://www.MedPAC.gov). ADDRESSES: MedPAC’s address is: 601 New Jersey Avenue, NW., Suite 9000, Washington, DC 2001. The telephone number is (202) 220–3700. FOR FURTHER INFORMATION CONTACT: Diane Ellison, Office Manager, (202) 220–3700. Mark E. Miller, Executive Director. [FR Doc. 05–4380 Filed 3–4–05; 8:45 am] BILLING CODE 6820–BW–M MILLENNIUM CHALLENGE CORPORATION [MCC FR 05–03] Revised Notice of March 14, 2005 Millennium Challenge Corporation Board of Directors Meeting; Sunshine Act Meeting Millennium Challenge Corporation. TIME AND DATE: 10 a.m.–12 p.m., Monday, March 14, 2005. PLACE: Department of State, C Street Entrance, Washington, DC 20520. FOR FURTHER INFORMATION CONTACT: Information on the meeting may be AGENCY: E:\FR\FM\07MRN1.SGM 07MRN1

Agencies

[Federal Register Volume 70, Number 43 (Monday, March 7, 2005)]
[Notices]
[Page 11032]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4290]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 2, 2004, Norac, 
Inc., 405 S. Motor Avenue, PO Box 577, Azusa, California 91702, made 
application by renewal to the Drug Enforcement Administration (DEA) for 
registration as a bulk manufacturer of THC Tetrahydrocannabinols 
(7370), a basic class of controlled substance listed in Schedule I.
    The company plans to manufacture the listed controlled substances 
in bulk for formulation into the pharmaceutical controlled substance 
marinol.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections being sent via regular mail may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, 
Washington, DC 20537, Attention: Federal Register Representative, 
Liaison and Policy Section (ODL) or any being sent via express mail 
should be sent to DEA Headquarters, Attention: DEA Federal Register 
Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 
22301; and must be filed no later than May 6, 2005.

    Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4290 Filed 3-4-05; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.